Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries
View as:

Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03926182 Org: User:
Start: 02/19/19 End: 04/03/19 Due: 04/03/20

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Phase: N/A Priority: Normal
NCT ID: NCT04121286 Org: User:
Start: 07/14/20 End: 06/17/22 Due: 06/17/23

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03127449 Org: User:
Start: 06/01/17 End: 01/08/24 Due: 01/08/25

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04720976 Org: User:
Start: 03/23/21 End: 12/19/23 Due: 12/19/24

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase: N/A Priority: Normal
NCT ID: NCT03787992 Org: User:
Start: 05/30/19 End: 03/31/26 Due: 03/31/27

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Phase: N/A Priority: Normal
NCT ID: NCT05466149 Org: User:
Start: 09/27/22 End: 12/31/26 Due: 12/31/27

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Phase: N/A Priority: Normal
NCT ID: NCT03452592 Org: User:
Start: 04/30/18 End: 03/14/24 Due: 03/14/25

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04858958 Org: User:
Start: 08/10/20 End: 08/31/25 Due: 08/31/26

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02973763 Org: User:
Start: 12/30/16 End: 08/01/23 Due: 08/01/24

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06970639 Org: User:
Start: 09/26/24 End: 09/30/29 Due: 09/30/30

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06955988 Org: User:
Start: 03/04/25 End: 06/30/27 Due: 06/30/28

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06956001 Org: User:
Start: 11/19/24 End: 07/31/28 Due: 07/31/29

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Phase: N/A Priority: Normal
NCT ID: NCT06008288 Org: User:
Start: 10/27/23 End: 11/30/25 Due: 11/30/26

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04958967 Org: User:
Start: 10/01/21 End: 08/01/22 Due: 08/01/23

Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03941340 Org: User:
Start: 04/08/19 End: 09/06/19 Due: 09/06/20

A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

Phase: N/A Priority: Normal
NCT ID: NCT07010419 Org: User:
Start: 05/28/25 End: 04/30/32 Due: 04/30/33

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04853342 Org: User:
Start: 06/07/21 End: 01/31/30 Due: 01/31/31

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05288205 Org: User:
Start: 04/14/22 End: 03/31/26 Due: 03/31/27

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06416410 Org: User:
Start: 08/07/24 End: 02/28/27 Due: 02/28/28

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06162169 Org: User:
Start: 11/25/23 End: 02/20/24 Due: 02/20/25

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05194995 Org: User:
Start: 02/17/22 End: 01/31/26 Due: 01/31/27

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Phase: N/A Priority: Normal
NCT ID: NCT05276726 Org: User:
Start: 08/17/22 End: 02/28/26 Due: 02/28/27

Mass Balance Study of [14C]JAB-21822

Phase: N/A Priority: Normal
NCT ID: NCT05920941 Org: User:
Start: 07/08/23 End: 08/09/23 Due: 08/09/24

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Phase: N/A Priority: Normal
NCT ID: NCT05009329 Org: User:
Start: 07/26/21 End: 12/31/25 Due: 12/31/26

A Food Effect Study of JAB-21822 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05875493 Org: User:
Start: 05/12/23 End: 06/14/23 Due: 06/14/24